These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19856075)

  • 1. Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer.
    Suzuki S; Ishikawa K
    J Infect Chemother; 2009 Oct; 15(5):335-9. PubMed ID: 19856075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy.
    Yokota T; Onozawa Y; Boku N; Hamauchi S; Tsushima T; Taniguchi H; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H
    Jpn J Clin Oncol; 2011 Dec; 41(12):1351-7. PubMed ID: 21980053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient oral chemotherapy with S-1 for unresectable or distant metastatic head and neck cancer.
    Maeda M; Yamashita T; Matsunobu T; Araki K; Tomifuji M; Shiotani A
    Anticancer Res; 2013 Aug; 33(8):3285-9. PubMed ID: 23898093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outpatient chemotherapy with S-1 for recurrent head and neck cancer.
    Yamashita T; Shinden S; Watabe T; Shiotani A
    Anticancer Res; 2009 Feb; 29(2):577-81. PubMed ID: 19331206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.
    Kim HS; Kim HR; Kim GM; Kim HS; Koh YW; Kim SH; Choi EC; Hong YK; Sung JH; Kim SM; Kim JH; Cho BC
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):539-46. PubMed ID: 22868340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)].
    Inuyama Y; Kida A; Tsukuda M; Kohno N; Satake B
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1151-8. PubMed ID: 9679577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Late phase II study of S-1 in patients with advanced head and neck cancer].
    Inuyama Y; Kida A; Tsukuda M; Kohno N; Satake B;
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1381-90. PubMed ID: 11681245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and toxicity of adjuvant chemotherapy using S-1 granules for local advanced squamous cell carcinoma of the head and neck.
    Suzuki S; Honda K; Sato T; Yamazaki K; Ishikawa K
    J Chemother; 2015 Oct; 27(5):297-300. PubMed ID: 25971448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer.
    Tsukuda M; Kida A; Fujii M; Kono N; Yoshihara T; Hasegawa Y; Sugita M;
    Br J Cancer; 2005 Oct; 93(8):884-9. PubMed ID: 16189518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consecutive daily low-dose S-1 adjuvant chemotherapy after radical treatment for squamous cell carcinoma in head and neck cancer.
    Furusaka T; Tanaka A; Matsuda H; Ikeda M
    Acta Otolaryngol; 2011 Oct; 131(10):1099-103. PubMed ID: 21651316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Indication of alternate-day treatment with S-1 in patients with oral cancer].
    Negishi A; Ogawa M; Kosugi K; Takayama Y; Gomi A; Miyazaki H; Yokoo S
    Gan To Kagaku Ryoho; 2015 May; 42(5):569-73. PubMed ID: 25981649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical usefulness of the oral chemotherapy agent S-1 in heavily pre-treated patients with advanced or recurrent cervical cancer.
    Tanigawa T; Matoda M; Yamamoto A; Nomura H; Okamoto S; Sakamoto K; Kondo E; Omatsu K; Kato K; Takeshima N
    Arch Gynecol Obstet; 2016 Mar; 293(3):633-8. PubMed ID: 26305033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Results of chemotherapy in head and neck cancer patients with residual or recurrent tumors after initial treatment].
    Katsuno M; Watanabe N; Sugio Y; Tachibana S; Tani Y; Sato N; Zusho H
    Gan To Kagaku Ryoho; 2010 Nov; 37(11):2109-13. PubMed ID: 21084809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study.
    Kubota A; Nakatani E; Tsukahara K; Hasegawa Y; Takemura H; Terada T; Taguchi T; Nagahara K; Nakatani H; Yoshino K; Higaki Y; Iwae S; Beppu T; Hanamure Y; Tomita K; Kohno N; Kawabata K; Teramukai S; Fujii M;
    PLoS One; 2018; 13(6):e0198391. PubMed ID: 29883463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis.
    Peng PJ; Cheng H; Ou XQ; Zeng LJ; Wu X; Liu YM; Lin Z; Tang YN; Wang SY; Zhang HY; Chen ZB
    Drug Des Devel Ther; 2014; 8():1083-7. PubMed ID: 25152614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adverse reactions to TS-1 for outpatients with recurrent head and neck cancer].
    Nishino H; Shinozaki T; Ishikawa K; Tanaka H; Ichimura K
    Gan To Kagaku Ryoho; 2002 Nov; 29(11):2019-23. PubMed ID: 12465408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical efficacy of administration with S-1 alone for head and neck carcinoma].
    Tsukuda M; Ishitoya J; Mikami Y; Matsuda H; Katori H; Horiuchi C; Taguchi T; Yoshida T; Toth G
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():144-9. PubMed ID: 16897991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
    Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
    Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
    Tsuchiya T; Nagayasu T; Yamasaki N; Matsumoto K; Miyazaki T; Tagawa T; Nakamura A; Minami H; Taniguchi H; Akamine S; Hisano H; Taniguchi Y
    Clin Lung Cancer; 2012 Nov; 13(6):464-9. PubMed ID: 22424872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
    Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.